Compare KARO & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | AMPH |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2021 | 2014 |
| Metric | KARO | AMPH |
|---|---|---|
| Price | $46.14 | $27.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $58.25 | $31.00 |
| AVG Volume (30 Days) | 32.9K | ★ 368.3K |
| Earning Date | 01-16-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 18.61 | N/A |
| EPS | 1.82 | ★ 2.27 |
| Revenue | $282,977,939.00 | ★ $723,305,000.00 |
| Revenue This Year | $21.18 | $1.35 |
| Revenue Next Year | $15.95 | $5.10 |
| P/E Ratio | $24.44 | ★ $11.77 |
| Revenue Growth | ★ 14.75 | N/A |
| 52 Week Low | $35.88 | $20.39 |
| 52 Week High | $63.36 | $39.01 |
| Indicator | KARO | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 59.11 |
| Support Level | $44.34 | $26.02 |
| Resistance Level | $47.70 | $27.23 |
| Average True Range (ATR) | 1.21 | 0.83 |
| MACD | -0.20 | 0.06 |
| Stochastic Oscillator | 59.29 | 98.46 |
Karooooo Ltd is a provider of real-time mobility data analytics solutions for smart transportation. It offers a comprehensive, cloud-based smart mobility platform for connected vehicles and other assets. The company's software-as-a-service platform provides customers with differentiated insights and analytics to optimize business and workforce, increase efficiency and decrease costs, improve safety, monitor environmental impact, assist with regularity compliance, and manage risk. The segments of the group are Cartrack; Carzuka; and Karooooo Logistics, of which key revenue is derived from the Cartrack segment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.